Abstract Number: 1573 • ACR Convergence 2022
Von – Willebrand Factor, a Possible Marker for Disease Activity in Vasculitis
Background/Purpose: Vasculitis is an inflammation of blood vessels. While in many cases markers of inflammation as c- reactive protein (CRP) or erythrocytes sedimentation rate (ESR)…Abstract Number: 0438 • ACR Convergence 2022
Characterization of Interstitial Lung Disease in the Presence of Antineutrophil Cytoplasmic Antibodies
Background/Purpose: Various pulmonary manifestations may occur in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). ANCA-related interstitial lung disease (ILD) has recently been described in…Abstract Number: 1688 • ACR Convergence 2022
Biomechanical Phenotype of Circulating Neutrophils Is Altered in ANCA Associated Vasculitis
Background/Purpose: Real Time-Deformability Cytometry (RT-DC) is a novel technique able to identify morpho-rheological characteristics of individual cells such as size, deformability, and elasticity using only…Abstract Number: 0439 • ACR Convergence 2022
Clinical Characteristics of Patients with ANCA-Associated Vasculitis with and Without Alpha-1 Antitrypsin Deficiency Alleles
Background/Purpose: There are multiple reasons to suspect that alpha-1 antitrypsin (A1AT) genotype impacts disease characteristics in ANCA-associated vasculitis (AAV). A1AT serves as the predominant endogenous…Abstract Number: 1928 • ACR Convergence 2022
Idiopathic Pulmonary Capillaritis Within the Spectrum of Pediatric Diffuse Alveolar Hemorrhage
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a life-threatening syndrome with bleeding from the pulmonary microvasculature. It is classified as pulmonary capillaritis if histology shows neutrophilic…Abstract Number: 0442 • ACR Convergence 2022
Induction Therapy Patterns for Severe ANCA-associated Vasculitis Differ Based on Physician Specialty, Expertise, and Practice Setting: An International Survey
Background/Purpose: Therapies for ANCA-associated vasculitis (AAV) have evolved over the last 3 decades. In light of new data on plasma exchange (PLEX) and glucocorticoid (GC)…Abstract Number: 1948 • ACR Convergence 2022
Clinical Characteristics and Outcomes of Pediatric ANCA-Associated Vasculitis Patients: Single-Center Inception Cohort
Background/Purpose: ANCA associated vasculitis (AAV) is a chronic autoimmune disorder characterized by ANCA production and small vessel inflammation and necrosis. ANCA autoantigen targets include myeloperoxidase…Abstract Number: 0443 • ACR Convergence 2022
Prognosis of Non-PR3 ANCA-Associated Vasculitis with Glomerulonephritis
Background/Purpose: Immunosuppressive treatments have improved the prognosis of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV), transforming these formerly fatal diseases into chronic conditions, with periods of…Abstract Number: 0450 • ACR Convergence 2022
Incidence of Solid and Hematologic Tumors in Patients with ANCA: A 10-year Retrospective Cohort Study
Background/Purpose: Serum antineutrophil cytoplasmic antibodies (ANCA) are significantly associated with the development of ANCA-associated vasculitides (AAV) but may also be detected in patients with other…Abstract Number: 0457 • ACR Convergence 2022
A Systematic Literature Review Informing the 2022 Update of the EULAR Recommendations for the Management of ANCA-associated Vasculitis
Background/Purpose: Since the publication of the 2016 European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of ANCA-associated vasculitis (AAV), the publication of…Abstract Number: 0513 • ACR Convergence 2022
The Association Between Age of Diagnosis and Disease Characteristics and Damage in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Background/Purpose: Clinical characteristics and outcomes often differ between children and adults diagnosed with the same rheumatic condition; however, such comparative data is limited in ANCA-associated…Abstract Number: 0526 • ACR Convergence 2022
Characteristics and Outcomes of Participants with and Without Diffuse Alveolar Hemorrhage in the Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis (PEXIVAS) Trial
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening manifestation of ANCA-associated vasculitis (AAV). Studies describing patients with DAH in AAV have typically been small…Abstract Number: 1072 • ACR Convergence 2022
Efficacy and Safety Assessment of a Rituximab Biosimilar in Patients with Granulomatosis with Polyangiitis (GPA)
Background/Purpose: A biosimilar is a medication that is highly similar to a biologic agent that is already approved by a regulatory organization. Considering the share…Abstract Number: 1073 • ACR Convergence 2022
Analysis of Clinical Outcomes in ANCA-associated Vasculitis Treated with Rituximab: Eighty Years a Single Center Experience in Japan
Background/Purpose: Contrary to many Western countries, MPO-ANCA-associated vasculitis (MPO-AAV) is dominant in Japan. The therapeutic response to rituximab (RTX) may differ. Therefore, we conducted a…Abstract Number: 0418 • ACR Convergence 2021
Longitudinal Patterns of Renal Function in ANCA-Associated Vasculitis
Background/Purpose: Renal involvement is common in ANCA-associated vasculitis (AAV). Prior analyses show that end stage renal disease (ESRD) in AAV may be multifactorial. Little is…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 20
- Next Page »